Sanofi, Regeneron Allowed to Sell Cholesterol Drug, Pending an Appeal

A federal appeals court temporarily suspended a permanent injunction that bars Sanofi and Regeneron from selling their cholesterol drug Praluent, pending a final ruling on an appeal.

The U.S. Court of Appeals for the Federal Circuit granted the stay based on four factors, the most critical being whether the companies showed a strong likelihood to prevail in their appeal and whether they would be irreparably damaged in the absence of a stay.

Potential damages to other interested parties and public interests factored into the decision, but to a lesser degree, the court said. A final decision on the appeal is expected in the next several months.